Supplementary Table1. Baseline lipid profile and AIP between RA patients with cDMARDs, TNF-α inhibitor, tocilizumab, abatacept and JAKi

|  | RA patients with cDMARDs | RA patients with TNF-α inhibitor | RA patients with tocilizumab | RA patients with Abatacept | RA patients with JAKi | *P* |
| --- | --- | --- | --- | --- | --- | --- |
| (N=221) | (N=339) | (N=200) | (N=94) | (N=63) |
| Total cholesterol (mg/dL)  | 184.0 [160.0;203.0]† | 173.0 [148.0;196.5] † | 178.0 [152.5;199.0] | 177.0 [155.0;198.0] | 171.0 [146.0;195.5] | **0.024** |
| HDL-C (mg/dL)  | 56.0 [47.0;69.0] | 55.5 [47.0;67.0] | 55.0 [47.0;66.0] | 55.0 [46.0;65.0] | 55.0 [48.5;72.5] | 0.746 |
| LDL-C (mg/dL)  | 93.0 [65.0;118.0] ‡ | 82.0 [45.0;111.0] | 82.0 [ 0.0;109.0] ‡ | 90.0 [61.0;113.0] | 97.0 [66.5;116.0] | **0.021** |
| Triglyceride (mg/dL)  | 97.0 [72.0;139.0] | 90.0 [67.0;128.5] | 93.0 [68.0;117.0] | 89.0 [69.0;122.0] | 96.0 [74.5;127.0] | 0.268 |
| AIP  | -0.108 ± 0.292 | -0.144 ± 0.256 | -0.148 ± 0.243 | -0.124 ± 0.236 | -0.133 ± 0.251 | 0.473 |
| AIP category |  | 0.389\* |
|  Low risk (AIP<0.11) | 174 (78.7%) | 279 (82.3%) | 171 (85.5%) | 79 (84.0%) | 53 (84.1%) |
|  Intermediate risk (0.11≤AIP≤0.21) | 18 ( 8.1%) | 26 ( 7.7%) | 16 ( 8.0%) | 8 ( 8.5%) | 7 (11.1%) |
|  High risk (AIP>0.21) | 29 (13.1%) | 34 (10.0%) | 13 ( 6.5%) | 7 ( 7.4%) | 3 ( 4.8%) |

\* The Mantel–Haenszel χ2 test was used.

† Significant difference in total cholesterol demonstrated by post-hoc analysis via Tukey method.

‡ Significant difference in LDL-C demonstrated by post-hoc analysis via Tukey method

AIP, atherogenic index of plasma; cDMARDs, conventional disease-modifying antirheumatic drugs; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; JAKi, janus kinase inhibitor; TNF-α, tumor necrosis factor α